The NeurologyLive® headache and migraine clinical focus page offers information, podcasts, videos, and news and interviews with physicians related to the care of patients with headache disorders such as chronic and episodic migraine, cluster headache, tension-type headache, and more. The page includes updates on the latest FDA actions, clinical guidelines, and study and clinical trial findings.
April 9th 2025
Relative to previously approved therapies like rimegepant, ubrogepant, and zavegepant, AXS-07 resulted in better 2-hour pain relief, sustained pain relief, and reduced use of rescue medications.
Burst Expert Illustrations & Commentary™: Visualizing the Role of FcRN in Neurological Disorders
View More
BURST Expert Illustrations and Commentaries™: Visualizing FcRn as a Therapeutic Target in Neurological Disease
View More
BURST Expert Illustrations and Commentaries™: Visualizing the Implications of FcRN-Targeted Therapies on Generalized Myasthenia Gravis
View More
Clinical Consultations™: Navigating the Evolving Treatment Landscape in Generalized Myasthenia Gravis
View More
Burst Expert Illustrations & Commentary™: Visualizing the Role of Subcutaneous Infusion as an Alternate Administration Route for Medical Interventions
View More
SimulatED™: Diagnosing and Treating Alzheimer’s Disease in the Modern Era
View More
SimulatED™: Understanding the Role of Genetic Testing in Patient Selection for Anti-Amyloid Therapy
View More
Expert Illustrations & Commentaries™: New Targets for Treatment in Cognitive Impairment in Schizophrenia – The Role of NMDA Receptors and Co-agonists
View More
BURST CME™ Part I: Understanding the Impact of Huntington’s Disease
View More
Burst CME™ Part II: The Evolving Treatment Landscape for Huntington Disease
View More
Carolina Neuromuscular Disease Summit
September 27, 2025
Register Now!
SimulatEd™ From Discomfort to Relief: Acute Pain Management Essentials
View More
Evolving Perspectives in Alzheimer's Disease: Reaching an Earlier Diagnosis, Understanding Neuroinflammation, and Exploring Therapeutic Advances
View More
Clinical ShowCase: Developing a Personalized Treatment Plan for a Patient with Huntington’s Disease Associated Chorea
View More
Medical Crossfire®: Integrating Real-World Data to Improve Outcomes for Patients With Multiple Sclerosis
View More
Medical Crossfire® - Optimizing Management for Patients With Generalized Myasthenia Gravis: Focus on Complement Inhibitors
View More
Burst CME™: Setting the Stage – Individualizing Migraine Care for Diverse Populations Across Care Settings
View More
Burst CME™: The Patient Journey – Unmet Needs From Diagnosis Through Management of Migraine
View More
Evolving Perspectives in Alzheimer Disease : Reaching an Earlier Diagnosis, Understanding Neuroinflammation, and Exploring Therapeutic Advances
View More
Burst CME™: Optimizing the Use of CGRP Targeted Agents for the Treatment of Migraine
View More
Burst CME™: Optimizing Migraine Management – Addressing Unmet Needs, Individualizing Care for Diverse Populations, and Utilizing CGRP Targeted Agents
View More
Community Practice Connections™: Optimizing the Management of Tardive Dyskinesia—Addressing the Complexity of Care With Targeted Treatment
View More
Cases and Conversations™: Applying Best Practices to Prevent Shingles in Your Practice
View More
Patient, Provider, and Caregiver Connection™: Pediatric Myasthenia Gravis—Current Treatment and Emerging Concepts
View More
Mind Moments™: Optimizing Management for Patients with Generalized Myasthenia Gravis
View More
Identifying and Treating CIDP in the Modern Era
View More
Cases and Conversations™: Navigating the Complexities of Managing Myasthenia Gravis in Pediatric and Pregnant Patient Populations
View More
Cases and Conversations™: Little Voices, Big Challenges – Comprehensive Care for Pediatric Spinal Muscular Atrophy
View More
A Breath of Strength: Managing Cancer Associated LEMS and Lung Cancer as One
View More
Striking the Right Nerve: Managing Cancer Associated LEMS in Lung Cancer Patients
View More
Gore Explores Migraine Treatment Using Patent Foramen Ovale Closure in New Study
November 15th 2022The newly announced prospective, randomized, placebo- and sham-controlled study, will include 150 patients, ages 18 to 55 years, with documented patent foramen ovale and a history of more than 1 migraine headache day per week.
Phase 2/3 Results of Zavegepant Showcase Effectiveness as Acute Migraine Medication
November 15th 2022Evidence of therapeutic benefit for zavegepant was observed on multiple secondary end points, including return to normal function at 30 min postdose, sustained pain relief, and sustained pain freedom.
Advocacy and Empowerment: Finding Your Advocacy Community
November 9th 2022The Palatucci Advocacy Leadership Forum, or PALF, sponsored by the American Academy of Neurology, gives neurologists and trainees tools to successfully advocate for their ideas and develop their identity as physician advocates.
Medical Crossfire on the Paradigm Shifts in Migraine Therapy: Jessica Ailani, MD
October 24th 2022The director of the MedStar Georgetown University Hospital Headache Center tells her experience in a medical crossfire as the migraine cochair at the fourth annual International Congress on the Future of Neurology. [WATCH TIME: 5 minutes]
The Benefits of Cross-Specialty Interaction at IFN 2022: Jessica Ailani, MD
October 23rd 2022The director of the MedStar Georgetown University Hospital Headache Center shares her experience as the migraine cochair at the fourth annual International Congress on the Future of Neurology. [WATCH TIME: 5 minutes]
NeurologyLive® Brain Games: October 23, 2022
October 23rd 2022Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is the history of the European Committee for Treatment and Research in Multiple Sclerosis.
Nerivio Remote Electrical Neuromodulation Meets Primary End Point in Preventive Migraine Study
October 22nd 2022In a traditional placebo-controlled trial, Nerivio outperformed placebo in the reduction monthly migraine days and monthly headache days, regardless of chronic or episodic migraine status.